Try a new search

Format these results:

Searched for:

in-biosketch:true

person:aizera01

Total Results:

123


Multi-modal AI: Integrating electrocardiography with molecular biomarkers for noninvasive detection of cardiac allograft rejection

Chen, K; Koesmahargyo, V; Ronan, R; Barbhaiya, C R; Bernstein, S A; Kushnir, A; Garber, L; Yang, F; Aizer, A; Reyentovich, A; Chinitz, L A; Goldberg, R I; Jankelson, L
UNLABELLED:Noninvasive rejection biomarkers (AlloMap, AlloSure) demonstrate high negative predictive value but positive predictive values of only 10-30%, driving avoidable endomyocardial biopsies. We developed a multi-modal AI model integrating electrocardiography with molecular biomarkers in 389 heart transplant recipients (5338 ECG-biopsy pairs), performing the first head-to-head comparison of AI-ECG, AlloMap, AlloSure, and their integration against biopsy-proven rejection. Individual modalities showed modest discrimination (AI-ECG AUC 0.65; AlloSure 0.67; AlloMap 0.56), while combining biomarkers alone did not improve performance (AUC 0.65). In the multi-modal test subset of ECGs (n=38, 2 rejection events), the integrated model achieved AUC 0.81 with 100% specificity (0/36 false positives) and 97% negative predictive value, eliminating all 19 false-positive combined-biomarker referrals. These hypothesis-generating results support prospective multi-center validation to determine whether requiring concordance across electrical and biomarker signals reduces unnecessary biopsies while preserving high negative predictive value. BACKGROUND/UNASSIGNED:Noninvasive rejection biomarkers (AlloMap gene-expression profiling (GEP); AlloSure donor-derived cell-free DNA (dd-cfDNA)) deliver high negative predictive value but positive predictive values of only 10-30%, driving avoidable endomyocardial biopsies. Each biomarker interrogates a single biological compartment. Whether integrating AI-enabled electrocardiography (AI-ECG) with these molecular assays improves specificity has not been tested. METHODS/UNASSIGNED:We retrospectively assembled 5338 unique ECG-endomyocardial-biopsy pairs from 389 adult heart transplant recipients at a single center (2018-2024). A ResNet-18 convolutional neural network was trained on 8-lead ECG waveforms with clinical covariates. In the 340-patient subset with same encounter AlloMap and AlloSure testing (405 ECG-biomarker-biopsy triplets), an integrated model fused the ECG embedding with biomarker values via late concatenation. We performed the first head-to-head, same-cohort comparison of AI-ECG, AlloMap, AlloSure, and their integration against biopsy-proven rejection (ISHLT ≥2R ACR or pAMR ≥2). Discrimination was evaluated with bootstrap 95% confidence intervals. RESULTS/UNASSIGNED:Individual modalities showed modest discrimination (AI-ECG AUC 0.65, 95% CI 0.58-0.72; AlloSure 0.67, 0.56-0.78; AlloMap 0.56, 0.46-0.67); combining biomarkers alone did not improve performance (AUC 0.65). In the multi-modal test subset (n=38 ECG-biopsy pairs, 2 rejection events), the integrated model achieved AUC 0.81 (0.50-1.00), 100% specificity (36/36; Clopper-Pearson 90-100%), and 97% NPV. At the same NPV threshold, all 19 false-positive combined-biomarker referrals in this subset would have been avoided, though this estimate reflects a single operating point in a small sample. AUC gains over single modalities did not reach statistical significance (DeLong p=0.31-0.34) given the limited event count. CONCLUSIONS/UNASSIGNED:A multi-modal AI model that requires concordance across electrical, immune-transcriptional, and donor-DNA signals showed numerically higher specificity for cardiac allograft rejection than any single modality, although the corresponding AUC differences did not reach statistical significance. These hypothesis-generating findings suggest that cross-compartment concordance may help discriminate true rejection from biomarker noise, but the small multi-modal test set precludes definitive conclusions; a pre-specified prospective multi-center trial powered for ≥50 rejection events is the necessary next step to test this hypothesis.
PMCID:13718866
PMID: 42960308
ISSN: 2950-1334
CID: 6074805

Spatial Transcriptomic Signatures of Cardiac Sarcoidosis

Foong, YH; Singh, A; Malik, M; Zhou, F; Liu, C; Willett, D; Golombeck, D; Zuluaga, T; Le, H; Caplan, AS; DurĂ¡n, JGB; Fishman, GI; Aizer, A; Reyentovich, A; Peyster, E; Goldberg, RI; Vanguri, R
ORIGINAL:7248934
ISSN: 3050-6611
CID: 6073700

Leadless Pacemaker Implant Location as a Predictor of Pacing Induced Cardiomyopathy

Kushnir, Alexander; Aboelatta, Mones; Donnino, Robert; Holmes, Douglas; Barbhaiya, Chirag R; Bernstein, Scott; Jankelson, Lior; Aizer, Anthony; Garber, Leonid; Chinitz, Larry A
BACKGROUND:Leadless pacemakers (LPs) avoid the lead- and pocket-related complications of transvenous systems, but they pace exclusively from the right ventricle (RV), and chronic RV pacing carries a recognized risk of pacing-induced cardiomyopathy (PICM). Whether implant location within the RV, a potentially modifiable factor, contributes to this risk has not been established. METHODS:Patients undergoing LP implantation with ≥50% RV pacing, pre-and post-procedural echocardiograms, and post-implant 3-dimensional radiographic imaging were included. All implants targeted the RV septum per manufacturer recommendation. PICM was defined as ≥10% decline in left ventricular ejection fraction (LVEF) to <50% without alternative cause. RESULTS:PICM developed in 20/81 patients (24.7%), with LVEF declining from 61±8% to 37±9%. Post-implant 3-dimensional radiographic imaging demonstrated inadvertent free wall implantation in 15/20 patients who developed PICM (75%) compared with 8/61 patients who did not (13%; P <0.001). Paced QRS duration was wider in patients with PICM than in those without (186±19 vs 155±13 ms, P <0.001) and discriminated free wall from non-free wall implantation with an area under the receiver operating characteristic curve (AUC) of 0.85; a QRS duration of 172 ms provided optimal discrimination. Baseline LVEF, baseline QRS duration, and comorbidity burden did not differ between groups. CONCLUSIONS:Inadvertent free wall LP implantation is strongly associated with the subsequent development of PICM. Paced QRS duration is a readily available surrogate for implant location, and targeting a paced QRS duration below approximately 172 ms at the time of implant may serve as a practical, non-invasive check on appropriate septal placement.
PMID: 42745207
ISSN: 1540-8159
CID: 6072899

Elongated Channels Between Surgically Excluded LAA and LA: Detected by CTA But Missed by TEE [Case Report]

Asachi, Parsa; Vainrib, Alan; Loulmet, Didier F; Hage, Ali; Aizer, Anthony; Chinitz, Larry A; Ro, Richard; Saric, Muhamed
BACKGROUND:Systematic left atrial appendage (LAA) exclusion during mitral valve surgery reduces thromboembolic risk in patients with pre- or postoperative atrial fibrillation. Rare residual LAA-left atrial (LA) communications may occasionally occur after surgical exclusion and increase thromboembolic risk, particularly in patients not receiving anticoagulation. CASE SERIES/METHODS:Among more than 2,000 robotic mitral valve surgeries performed at NYU Langone Health from 2010 to 2025, LAA closure with LA posterior wall plication was performed using a continuous back-and-forth suture technique. We identified 4 patients with elongated residual LAA-LA communications that were occult on transesophageal echocardiography (TEE) but clearly visualized by cardiac computed tomography angiography (CCTA). TEE demonstrated persistent echolucency and color Doppler flow within the excluded LAA without a visible communication entrance. A tubular channel extending from the LAA, termed the "panhandle sign," was consistently observed. CCTA identified the communication orifices and guided successful transcatheter vascular plug closure. CONCLUSIONS:Rare elongated residual LAA-LA communications may be missed on routine TEE after LAA exclusion with LA plication. Persistent LAA flow and echolucency should prompt CCTA to detect occult communications and guide percutaneous closure. The "panhandle sign" may represent an imaging marker specific to our institutional extended-suture technique that facilitates earlier recognition.
PMID: 42684242
ISSN: 2666-0849
CID: 6071966

Pulmonary Vein Isolation (PVI) Versus PVI With Posterior Wall Isolation With PFA for Paroxysmal Atrial Fibrillation

Junarta, Joey; Wang, Angela; Reynolds, Eli; Hatzimemos, Aristides; Patel, Pooja; Shields, Danielle; Yang, Felix; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Kushnir, Alexander; Garber, Leonid; Bernstein, Scott A; Park, David S; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:The value of additional lesion sets beyond pulmonary vein isolation (PVI) for atrial fibrillation (AF) ablation is unclear. However, existing studies evaluated the utility of substrate modification with conventional energy sources. There is limited data evaluating PVI with posterior wall isolation (PWI) using pulsed field ablation (PFA). METHODS:We studied consecutive cases of patients with paroxysmal AF undergoing first-time ablation with PFA between May 6, 2024 and March 10, 2025. Procedural data collected included the number of PFA applications administered, total procedure time, and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at 1-year follow-up. Outcomes were compared in patients undergoing PVI alone versus PVI plus PWI. RESULTS:A total of 249 patients were included in this study (104 PVI alone, 145 PVI plus PWI). There was no difference in ATA recurrence by Kaplan-Meier survival analysis comparing PVI alone versus PVI plus PWI (log rank test p = 0.89). When comparing PVI alone versus PVI plus PWI, there was no difference in ATA recurrence at 1 year (16% vs. 16%; p = 0.92), AF burden on continuous monitoring (2% vs. 2%; p = 0.81), total procedure time (114 vs. 107 min; p = 0.14), or major periprocedural complications (0 vs. 3; p = 0.14). CONCLUSION/CONCLUSIONS:PFA for paroxysmal AF with PVI alone or PVI plus PWI produces similar sinus rhythm maintenance without affecting procedure times or complication rates.
PMID: 42631424
ISSN: 1540-8159
CID: 6071528

The Utility of Higher Pulsed Field Ablation Applications for Atrial Fibrillation Ablation

Junarta, Joey; Reynolds, Eli; Wang, Angela; Hatzimemos, Aristides; Patel, Pooja; Shields, Danielle; Yang, Felix; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Kushnir, Alexander; Garber, Leonid; Bernstein, Scott A; Park, David S; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:The optimal number of pulsed field ablation (PFA) applications during atrial fibrillation (AF) ablation is unclear. We hypothesized that the number of PFA applications would predict atrial tachyarrhythmia (ATA) recurrence rates. OBJECTIVE:To determine whether higher numbers of PFA applications would decrease ATA recurrence rates. METHODS:We studied cases of patients with AF undergoing first-time ablation with PFA between 5/6/24 and 10/7/24. All patients underwent pulmonary vein and posterior wall isolation. The primary outcome was ATA recurrence. Additional outcomes included stroke, post-procedural acute kidney injury (AKI), total procedure time, and major periprocedural complications. Univariable and multivariable analyses were performed to determine if the number of PFA applications predicted ATA recurrence. RESULTS:In a cohort consisting of 177 patients, univariable and multivariable analysis showed that the number of PFA applications split at the smallest quartile (< 57 applications) versus the largest three quartiles (≥ 57 applications) was the strongest predictor of ATA recurrence (p = 0.03). ATA recurrence at 1 year (29% vs. 8%; p < 0.01) and AF burden on continuous monitor (4% vs. 0%; p < 0.01) was higher with the standard (< 57 applications) vs higher (≥ 57 applications) PFA dose groups. When comparing the standard versus higher PFA dose groups, there was no difference in total procedure time (106 vs. 107 min; p = 0.77), major periprocedural complications (0% vs. 2%; p = 0.33), or post-procedural AKI (2% vs. 2%; p = 0.69). CONCLUSION/CONCLUSIONS:Increasing number of PFA applications is associated with reduced ATA recurrence. A higher number of PFA applications may decrease ATA recurrence without affecting procedure times or complication rate.
PMCID:13372387
PMID: 42189098
ISSN: 1540-8167
CID: 6066212

Buckled Transesophageal Echocardiography Probe: A Stepwise Approach to Diagnosis and Management of a High-Risk Complication [Case Report]

Ho, Alvin M; Hammad, Sara O; Bamira, Daniel; Vainrib, Alan; Ro, Richard; Aizer, Anthony; Holmes, Douglas; Chinitz, Larry; Freedberg, Robin S; Saric, Muhamed
BACKGROUND:Buckling of a transesophageal echocardiography (TEE) probe is a rare but potentially life-threatening complication that carries a significant risk of esophageal perforation. CASE SUMMARY/METHODS:We report 3 cases of buckled TEE probes that were promptly recognized, diagnosed, and managed using multimodal imaging. In each instance, the location of the buckled probe was confirmed with bedside imaging. Subsequently, the patient was taken to the interventional suite for advancement of the probe to the stomach under fluoroscopic guidance. Finally, the buckled TEE probe was straightened and removed successfully from the patient without difficulty. DISCUSSION/CONCLUSIONS:Early recognition of buckled TEE probes and employment of a structured, algorithmic management approach are essential to optimizing outcomes and preventing associated morbidity and mortality. TAKE HOME MESSAGES/CONCLUSIONS:Buckling of the TEE probe requires a high index of suspicion and prompt diagnosis to prevent catastrophic complications such as esophageal perforation. Advancement of the TEE probe in the stomach under fluoroscopic guidance facilitates straightening and removal of the probe without the risk of esophageal perforation.
PMID: 42283680
ISSN: 2666-0849
CID: 6048892

Vein of Marshall Ethanol Infusion for Recurrent Atrial Fibrillation Patients Presenting for Redo Ablation: A Systematic Review and Meta-Analysis

Junarta, Joey; Simadibrata, Daniel M; Wang, Angela; Hsia, Brian; Garber, Leonid; Barbhaiya, Chirag R; Jankelson, Lior; Park, David S; Holmes, Douglas; Kushnir, Alexander; Chinitz, Larry A; Aizer, Anthony
Randomized trials of ethanol infusion into the vein of Marshall (EIVOM) have shown efficacy in preventing atrial fibrillation (AF) recurrence in patients presenting for de novo ablation. The utility of EIVOM in AF patients who present for redo ablation is unclear. This meta-analysis was reported according to the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines. Medline, Scopus, and Cochrane Central Register of Controlled Trials were systematically searched to identify relevant studies. Risk of bias was assessed using the Modified Newcastle-Ottawa scale. Eligible studies reported outcomes in AF patients with previous ablation who underwent redo catheter ablation (CA) alone vs. combined redo CA and EIVOM. Five observational studies comprising 568 patients were included. When comparing combined redo CA and EIVOM vs. redo CA alone, pooled results showed no difference in freedom from arrhythmia (FFA) in all patients (risk ratio [RR] 1.13; 95% confidence interval [CI] 0.96-1.33), FFA in persistent AF patients only (RR 1.08; 95% CI 0.90-1.29), total procedure time (mean difference -0.59; 95% CI -41.04-39.85), or major periprocedural complications (RR 0.81; 95% CI 0.06-11.64). Patients with AF recurrence after ablation represent a difficult-to-treat population. Salvage therapy with combined CA and EIVOM did not improve arrhythmic outcomes compared to CA alone in AF patients who presented for redo ablation.
PMID: 42138590
ISSN: 1540-8167
CID: 6037132

The utility of high-frequency jet ventilation in pulsed field ablation for atrial fibrillation

Junarta, Joey; Reynolds, Eli; Wang, Angela; Patel, Pooja; Hatzimemos, Aristides; Shields, Danielle; Linton, Patrick; Yang, Felix; Barbhaiya, Chirag R; Jankelson, Lior; Holmes, Douglas; Park, David S; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:Using high-frequency jet ventilation (HFJV) to improve catheter stability with conventional energy sources during atrial fibrillation (AF) ablation is associated with higher ablation success and improved arrhythmic outcomes. The utility of HFJV with pulsed field ablation (PFA) for AF is unclear. We investigated the utility of HFJV vs. standard ventilation in PFA for AF. METHODS:We studied consecutive cases of patients with AF undergoing PFA between 5/6/24 to 10/10/24. Procedural data collected included total procedure time and major periprocedural complications. Clinical data collected included atrial tachyarrhythmia (ATA) recurrence, stroke, and major bleeding at one-year follow-up. Outcomes were compared in cases where HFJV was used vs. standard ventilation. RESULTS:A total of 512 patients were included in this study (307 standard ventilation, 205 HFJV). There was no difference in ATA recurrence by Kaplan-Meier survival analysis between standard ventilation and HFJV groups (log rank test p = 0.59). When comparing standard ventilation vs. HFJV groups, there was no difference in ATA recurrence at one year (23% vs. 26%; p = 0.43), AF burden on continuous monitoring (9 ± 5% vs. 8 ± 24%; p = 0.85), total procedure time (114 ± 38 vs. 115 ± 33 min; p = 0.78), or major periprocedural complications (3% vs. 2%; p = 0.64). There was no difference in arrhythmic outcomes when patients were stratified by AF type and whether patients presented for first-time or redo ablation. CONCLUSION/CONCLUSIONS:Using HFJV in PFA for AF produces similar sinus rhythm maintenance overall and when stratified by AF type without affecting procedure times or complication rate.
PMID: 42118506
ISSN: 1572-8595
CID: 6036602

Utility of Very High Output Pace-Capture Testing for Posterior Wall Isolation in Patients With Persistent Atrial Fibrillation

Hsia, Brian; Liebman, Jordan; Garber, Leonid; Yang, Felix; Spinelli, Michael; Malyshev, Yury; Kushnir, Alexander; Jankelson, Lior; Bernstein, Scott; Park, David; Barbhaiya, Chirag; Holmes, Douglas; Chinitz, Larry A; Aizer, Anthony
BACKGROUND:Pulmonary vein isolation (PVI) and posterior wall isolation (PWI) are frequently used in the treatment of persistent atrial fibrillation (AF). Minimal data support adjunct PWI, possibly due to lack of durability via epicardial reconnections. OBJECTIVE:To determine the impact of very high output PW pace-capture testing in patients with persistent AF on AF/AT recurrence. METHODS:We performed a retrospective study of consecutive patients who underwent radiofrequency ablation for persistent AF and received PVI and PWI, as well as a cavotricuspid isthmus line (CTI). After the creation of three linear PW lesions (roof, carina-to-carina, and inferior PV levels), pace-capture testing was performed on the PW. The first cohort confirmed PWI using 10 mA at 2 ms (10 × 2) to pace capture. Sequentially, the second cohort utilized 20 mA at 10 ms (20 × 10). If the PW was captured, additional lesions were performed. Patients were excluded if additional lesion sets beyond PVI, PWI, and CTI were performed. RESULTS:A total of 232 patients were included. Of these, 129 (56%) patients were in the 20 × 10 group, and 103 (44%) patients were in the 10 × 2 group. The two groups did not differ in age, sex, proportion of comorbidities, presenting rhythm, left ventricular ejection fraction, or left atrial size. Despite the increase in procedure time and lesion number, in the time-to-event analysis, patients in the 20 × 10 group experienced recurrent AF/AT more frequently than those in the 10 × 2 group (log rank p = 0.01). CONCLUSION/CONCLUSIONS:Testing PWI in persistent AF with pace capture at 20 mA at 10 ms did not improve freedom from arrhythmia and may paradoxically be associated with harm. Our findings question whether PWI, regardless of durability, is effective in treating persistent AF.
PMID: 41935974
ISSN: 1540-8167
CID: 6024862